This is an old blog post that is largely outdated. But we have a 2024 update at the bottom of the page and a current look back on what the Xarelto lawsuits were about.
Frequent readers of this blog will be aware of the litigation against Bayer/Johnson & Johnson regarding their drug Xarelto. The cases are consolidated in federal court as Multidistrict Litigation (MDL), and the presiding judge is moving proceedings along.
- November 2017 Update: we have not lost three of these cases in a row
- January 2018 Update: we just got a huge verdict that will change the course of this litigation forever
What Were the Xarelto Lawsuits About
The lawsuits against Bayer and Janssen Pharmaceuticals regarding Xarelto focused on serious allegations that the drug caused uncontrollable and sometimes fatal bleeding in patients. Plaintiffs claimed that the companies failed to provide adequate warnings about the significant risks associated with the anticoagulant, particularly the absence of an effective antidote to reverse its effects in emergencies. They argued that this lack of information led to severe, and in some cases, fatal bleeding incidents that could have been mitigated or prevented with proper warnings.
Moreover, the plaintiffs accused Bayer and Janssen of marketing Xarelto as a superior alternative to traditional anticoagulants like warfarin, emphasizing convenience over safety by understating the need for monitoring and overestimating the drug’s safety. They contended that Xarelto was defectively designed, lacking in dose flexibility needed to safely manage different patient conditions, and that it was brought to market without sufficient clinical testing to fully understand its risks.
The lawsuits included claims of negligence, asserting that the companies were negligent in their development, testing, and marketing practices. They were accused of prioritizing profit over patient safety, which allegedly led to injuries and deaths. This litigation raised significant concerns about pharmaceutical practices, regulatory oversight, and the balance between drug innovation and patient safety. The multitude of lawsuits eventually led Bayer and Janssen to agree to a $775 million settlement to resolve around 25,000 cases, without admitting to any wrongdoing, thus highlighting the complexities and responsibilities inherent in pharmaceutical development and marketing.
Summer 2015 Update
Over the past few years, product liability suits against the makers and marketers of the drug Xarelto, Bayer/Johnson & Johnson, have been cropping up across the country. The suits are mostly filed in federal court, meaning the parties consolidated them as an MDL. Judge Eldon Fallon is the sole judge presiding over the MDL, giving him the ability to make all pretrial rulings. This is the great thing about an MDL; when many different cases are consolidated, the parties can avoid doing the same discovery over and over again, while getting consistent rulings from a single judge.
Continue reading
